345 related articles for article (PubMed ID: 11868919)
21. Omalizumab as add-on therapy to inhaled steroids for asthma.
Hadj Tahar A
Issues Emerg Health Technol; 2004 Jun; (58):1-4. PubMed ID: 15455487
[TBL] [Abstract][Full Text] [Related]
22. Omalizumab in the treatment of severe asthma: efficacy and current problems.
Pelaia G; Renda T; Romeo P; Busceti MT; Maselli R
Ther Adv Respir Dis; 2008 Dec; 2(6):409-21. PubMed ID: 19124386
[TBL] [Abstract][Full Text] [Related]
23. A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.
D'Amato G; Piccolo A; Salzillo A; Noschese P; D'Amato M; Liccardi G
Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):225-31. PubMed ID: 19075985
[TBL] [Abstract][Full Text] [Related]
24. Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases.
Chang TW; Wu PC; Hsu CL; Hung AF
Adv Immunol; 2007; 93():63-119. PubMed ID: 17383539
[TBL] [Abstract][Full Text] [Related]
25. [Anti-IgE therapy].
Chazan R
Pol Merkur Lekarski; 2003 Jun; 14(84):617-20. PubMed ID: 14524285
[TBL] [Abstract][Full Text] [Related]
26. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma.
Kulus M; Hébert J; Garcia E; Fowler Taylor A; Fernandez Vidaurre C; Blogg M
Curr Med Res Opin; 2010 Jun; 26(6):1285-93. PubMed ID: 20377320
[TBL] [Abstract][Full Text] [Related]
27. Reduction of the total IgE level by omalizumab in children and adolescents.
Steiss JO; Strohner P; Zimmer KP; Lindemann H
J Asthma; 2008 Apr; 45(3):233-6. PubMed ID: 18415832
[TBL] [Abstract][Full Text] [Related]
28. Anti-IgE for the treatment of allergic rhinitis--and eventually nasal polyps?
Verbruggen K; Van Cauwenberge P; Bachert C
Int Arch Allergy Immunol; 2009; 148(2):87-98. PubMed ID: 18799888
[TBL] [Abstract][Full Text] [Related]
29. Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy.
Corren J; Shapiro G; Reimann J; Deniz Y; Wong D; Adelman D; Togias A
J Allergy Clin Immunol; 2008 Feb; 121(2):506-11. PubMed ID: 18269927
[TBL] [Abstract][Full Text] [Related]
30. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis.
Chervinsky P; Casale T; Townley R; Tripathy I; Hedgecock S; Fowler-Taylor A; Shen H; Fox H
Ann Allergy Asthma Immunol; 2003 Aug; 91(2):160-7. PubMed ID: 12952110
[TBL] [Abstract][Full Text] [Related]
31. Anti-IgE in severe persistent allergic asthma.
Fox H
Respirology; 2007 Nov; 12 Suppl 3():S22-8; discussion S45-7. PubMed ID: 17956516
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
[TBL] [Abstract][Full Text] [Related]
33. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma.
Sullivan SD; Turk F
Allergy; 2008 Jun; 63(6):670-84. PubMed ID: 18445184
[TBL] [Abstract][Full Text] [Related]
34. Omalizumab and the immune system: an overview of preclinical and clinical data.
Johansson SG; Haahtela T; O'Byrne PM
Ann Allergy Asthma Immunol; 2002 Aug; 89(2):132-8. PubMed ID: 12197568
[TBL] [Abstract][Full Text] [Related]
35. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma.
Bousquet J; Cabrera P; Berkman N; Buhl R; Holgate S; Wenzel S; Fox H; Hedgecock S; Blogg M; Cioppa GD
Allergy; 2005 Mar; 60(3):302-8. PubMed ID: 15679714
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
Ayres JG; Higgins B; Chilvers ER; Ayre G; Blogg M; Fox H
Allergy; 2004 Jul; 59(7):701-8. PubMed ID: 15180756
[TBL] [Abstract][Full Text] [Related]
37. [Omalizumab, an anti-IgE monoclonal antibody to treat severe asthma].
Michils A; Sternon J
J Pharm Belg; 2006; 61(3):83-7. PubMed ID: 17058881
[TBL] [Abstract][Full Text] [Related]
38. [Therapy with omalizumab in patients with severe persistent allergic asthma: a real life data in Turkey].
Bavbek S; Aydın O; Kepil Özdemir S; Yılmaz I; Celik GE; Demirel YS; Mungan D; Sin B; Kurşun N; Mısırlıgil Z
Tuberk Toraks; 2010; 58(4):425-34. PubMed ID: 21341120
[TBL] [Abstract][Full Text] [Related]
39. Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis.
Corren J; Diaz-Sanchez D; Saxon A; Deniz Y; Reimann J; Sinclair D; Davancaze T; Adelman D
Ann Allergy Asthma Immunol; 2004 Sep; 93(3):243-8. PubMed ID: 15478383
[TBL] [Abstract][Full Text] [Related]
40. Anti-immunoglobulin E (omalizumab) therapy in allergic asthma.
Busse WW
Am J Respir Crit Care Med; 2001 Oct; 164(8 Pt 2):S12-7. PubMed ID: 11704612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
